Anti-Mouse CD223 (LAG-3) - DyLight 488

Antibody Details

Product Details

Reactivity Species

Mouse

Host Species

Rat

Immunogen

Purified Recombinant Mouse LAG-3

Product Concentration

0.2 mg/ml

Formulation

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Handling

This DyLight^® 488 conjugate is stable when stored at 2-8°C. ^{Do not freeze}.

Country of Origin

USA

Shipping

Next Day 2-8°C

Excitation Laser

Blue Laser (493 nm)

RRID

AB_2829341

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone C9B7W recognizes and specifically binds to an epitope in the D2 domain of CD223.

Antigen Distribution

CD223 is expressed on T regulatory cells, activated T cells and NK cells.

Background

LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.

Antigen Details

Protein

CD223

PubMed

CD223

NCBI Gene Bank ID

16768

UniProt.org

Information on Uniprot.org

Research Area

Immunology

.

Inhibitory Molecules

Technical Protocols